ABBISKO-B(02256): Hengyi Pharmaceuticals announced the results of the ABSK061 combined with ABSK043 in the treatment of FGFR2-positive advanced GC/GEJC Phase II study at the 2026 ASCO Annual Meeting.

ABBISKO-B(02256) announced that its subsidiary Shanghai Huyu Biomedical Technology Co., Ltd. (Huyu Medicine) revealed at the recent 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, the company's independently developed first-in-class oral highly selective FGFR2/3 inhibitor ABSK061 combined with oral PD-L1 inhibitor ABSK043, with or without CAPOX (oxaliplatin plus capecitabine), showed promising preliminary results in a phase II clinical study for FGFR2-positive advanced gastric cancer and gastroesophageal junction cancer (GC/GEJC). The research data demonstrated that ABSK061 combined with ABSK043, with or without CAPOX, exhibited good safety and positive anti-tumor activity in FGFR2-positive advanced GC/GEJC patients, highlighting the potential of this targeted combination immunotherapy strategy as a novel treatment option for this patient population.